Acquired haemophilia A treated with recombinant porcine factor VIII: a single centre UK experience

2020 ◽  
Vol 189 (4) ◽  
Author(s):  
Dalia Khan ◽  
Sayma Raza‐Burton ◽  
Peter Baker ◽  
Sarah Harper ◽  
James Beavis ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia

scholarly journals Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome

Haemophilia ◽  
2021 ◽  
Author(s):  
Marika Porrazzo ◽  
Erminia Baldacci ◽  
Antonietta Ferretti ◽  
Maria Lucia De Luca ◽  
Francesco Barone ◽  
...  
Keyword(s):  
Clinical Management ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Single Centre Experience

Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy

Haemophilia ◽  
2016 ◽  
Vol 22 (5) ◽  
pp. e472-e474 ◽  
Author(s):  
M. Stemberger ◽  
P. Möhnle ◽  
J. Tschöp ◽  
L. Ney ◽  
M. Spannagl ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Bleeding Control ◽  
Acquired Haemophilia

scholarly journals Acquired haemophilia A caused by inhibitor against factor VIII.

2001 ◽  
Vol 90 (6) ◽  
pp. 1085-1087
Author(s):  
Noriko Kakudo ◽  
Tomohiro Sugawara ◽  
Yasuhide Asaumi ◽  
Tatsuyuki Sato ◽  
Mitsushi Yano ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Acquired Haemophilia

Does Peroral Administration of Factor VIII Induce Oral Tolerance in Patients with Acquired Haemophilia A?

2000 ◽  
Vol 83 (04) ◽  
pp. 632-633 ◽  
Author(s):  
Hans Wadenvik ◽  
Andrej Tarkowski ◽  
Lilian Tengborn ◽  
Arne Lindgren
Keyword(s):  
Factor Viii ◽  
Oral Tolerance ◽  
Peroral Administration ◽  
Haemophilia A ◽  
Acquired Haemophilia

Postpartum acquired haemophilia: a single centre experience with rituximab

Haemophilia ◽  
2009 ◽  
Vol 15 (5) ◽  
pp. 1166-1168 ◽  
Author(s):  
L. DEDEKEN ◽  
J. ST-LOUIS ◽  
C. DEMERS ◽  
C. MEILLEUR ◽  
G. E. RIVARD
Keyword(s):  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Single Centre Experience

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience

Haemophilia ◽  
2016 ◽  
Vol 22 (4) ◽  
pp. e338-e341 ◽  
Author(s):  
B. Rossi ◽  
P. Blanche ◽  
V. Roussel-Robert ◽  
A. Berezné ◽  
S. Combe ◽  
...  
Keyword(s):  
Haemophilia A ◽  
First Line ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Emicizumab in acquired haemophilia A: about two clinical cases and literature review

2021 ◽  
Vol 12 ◽  
pp. 204062072110381
Author(s):  
Amandine Hansenne ◽  
Cedric Hermans
Keyword(s):  
Autoimmune Disease ◽  
Literature Review ◽  
Factor Viii ◽  
Immunosuppressive Therapy ◽  
Current Literature ◽  
Mode Of Action ◽  
Bispecific Antibody ◽  
Haemophilia A ◽  
Acquired Haemophilia ◽  
Excess Morbidity

Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosuppressive therapy. Rapid recognition and proper management are essential to avoid excess morbidity and mortality. Effective and safe treatments can be challenging, given that AHA patients are often elderly, with multiple comorbidities. Emicizumab, a bispecific antibody that mimics the action of FVIII, has proven effective in managing patients with congenital haemophilia, with or without inhibitors. Likewise, its mode of action suggests theoretical efficacy in AHA patients. We herein describe two AHA cases with comorbidities that were treated effectively using emicizumab combined with immunosuppressive therapy. We have also reviewed the current literature regarding the promising use of emicizumab in this indication.

Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve

2020 ◽  
Vol 13 (9) ◽  
pp. e230798
Author(s):  
Lisa B Pinchover ◽  
Rami Alsharif ◽  
Talia Bernal
Keyword(s):  
Multiple Myeloma ◽  
Mitral Valve ◽  
Factor Viii ◽  
Primary Care Doctor ◽  
Factor Viii Inhibitor ◽  
Haemophilia A ◽  
Acquired Haemophilia ◽  
Viii Inhibitor ◽  
Spontaneous Haematoma ◽  
Acquired Factor Viii Inhibitor

A 77-year-old man with a mechanical mitral valve on warfarin presented with an acute drop in haemoglobin and large spontaneous haematoma. He was found to have a new coagulopathy with initial labs notable for a prolonged activated partial thromboplastin time (APTT). Further workup revealed factor VIII levels less than 1%, abnormal mixing studies and elevated Bethesda titres, which was consistent with an acquired factor VIII inhibitor. Given his bone marrow biopsy result, which was positive for plasma cell myeloma, this coagulopathy was thought to be an acquired haemophilia A secondary to multiple myeloma. Anticoagulation was a challenge in this patient given his mechanical mitral valve and acquired haemophilia A. Although the patient was at risk of thrombosis due to a mechanical mitral valve, he had a bleeding diathesis and anaemia not responsive to transfusion. The decision was made to hold anticoagulation and the patient was started on myeloma treatment which included CyBorD, rituximab and daratumumab. After initiation of treatment APTT and factor VIII normalised. He eventually restarted anticoagulation under direction of his primary care doctor.

Sign in / Sign up

Export Citation Format

Share Document